Olivia Vizier

Experts from Umoja Biopharma dive into cell therapy development in this episode of the Drug Solutions Podcast, including the greatest advancements in cell therapy to date, areas for improvement, the biggest trends in cell therapy development, and retention as a pain point.

The Founder of the Sepsis Alliance, Carl Flatley, is on a mission to raise awareness for sepsis, and he is doing so by riding his bike across the state of Florida to honor his daughter, Erin, who passed away because of sepsis.

We’re developing a pipeline of innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Our lead program, REN-001, is being developed for BAG3-associated dilated cardiomyopathy (DCM) and uses gene transfer technology to address the monogenic cause of this severe form of heart failure.

In July, SOTIO Biotech launched an aggressive phase 2 basket trial of its lead candidate, the IL-15-targeting SOT101, as monotherapy and in combination with pembrolizumab (Keytruda) in patients with selected relapsed/refractory advanced/metastatic solid tumors.

Etkin explains that in the cerebral cortex—the outermost layer of the brain—are systems responsible for a number of higher functions, including cognitive functions like planning,

Ashvattha Therapeutics today announced that the first patient has been enrolled in a two-stage Phase 2 clinical study of D-4517.2, an HDT with potent anti-VEGF activity.

Unlike many CFOs who tell us that their finance career paths did not intersect with the investor relations (IR) function until shortly before their arrival in the CFO office, Chuck Triano relates that his actually began inside the IR function.

As CEO of Portage Biotech, a clinical-stage company, Walters and his team are following a potentially disruptive scientific path to advance first-in-class immunotherapies that elevate or initiate the immune response across a range of cancer types.

Kathy Lee-Sepsick, the founder of Femasys, is determined to change the game in long-neglected areas of women’s healthcare, some of which haven’t had much innovation in more than a century.

A Navy veteran, former marathon runner, and father from Florida is riding to raise money for a deadly condition. He founded the group 20 years ago after his 23 year old daughter tragically died from sepsis. Carl Flatley traveled more than 200 miles and raised $35,000 last year. This year he has bigger goals.

Cell therapy is coming into its own as an effective therapeutic avenue for cancer. Into that fray in November 2019 launched Umoja Biopharma, whose unique immunotherapy approach aims to re-engineer a patient’s own immune system in vivo to attack and destroy hematologic and solid organ-based tumors.

At TFF Pharmaceuticals, our experience has offered important perspective on how strategically crafted CDMO partnerships can facilitate more efficient manufacturing and scale-up of complex modalities such as biologics.

Psychedelic medicine firm MindMed (Nasdaq: MNMD)has dosed the first patient in a Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD).

At TFF Pharmaceuticals, our experience has offered important perspective on how strategically crafted CDMO partnerships can facilitate more efficient manufacturing and scale-up of complex modalities such as biologics.

Recent years have seen a surge of research into rarer forms of kidney disease, with drug companies, regulators, and researchers alike hunting for ways to help patients who have few options.

In what instances should organizations outsource vs. insource? Determining the right outsourcing strategy is key to limit unnecessary costs, maintain output and turnaround times, and enable continued flexibility.

THBC is selling its platelets to local hospitals, which use them to help prevent bleeding in cancer patients as well as those undergoing surgery and organ transplants.

Overall, Ashvattha’s strategy will be to prioritise functional outcomes over surrogate markers, Cleland explains. The long Covid field still lacks any standardised clinical trial endpoints, making late-stage trial design a largely uncharted territory.

But he hopes that Sotio will prevail by focusing on patients who have previously failed checkpoint inhibitors and cancers in which these drugs have not worked.

Biotechnology startup Cerevance Inc. could earn more than $1 billion through a collaboration with drugmaker Merck & Co. to research potential treatments for Alzheimer’s disease.

With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.

Cerevance is a central nervous system disorders-focused biotech backed by Bill Gates. Its main program so far has been the Parkinson’s disease therapy CVN424, which

For the first time since discontinuing its late-stage Alzheimer’s program, Merck has found promise on the path forward in the memory-robbing disease.

Psychedelic medicine firm MindMed (Nasdaq: MNMD)has dosed the first patient in a Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD).

PORT-2 is an activator of this population. It has direct impact against tumors in terms of upregulating PD-L1 expression, which we know is favorable because it can

A broad range of serious diseases involve chronic inflammation, which causes both pain and progressive damage. Xalud Therapeutics is developing a locally-delivered, non-viral gene therapy that is designed to harness the ability of interleukin-10 to regulate the immune system and restore homeostasis. The company’s lead indication is in osteoarthritis We spoke to Diem Nguyen, CEO

In this episode, the editorial team spoke with the President and CEO of regenerative medicine biotech Sernova Corp Dr. Philip Toleikis to learn more about how the company is developing a ‘functional cure’ for diabetes.

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group is starting its phase 2 trial on patients with selected advanced/refractory solid tumors.

Brad Margus is co-founder and Executive Chairman of Cerevance, a drug discovery company advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease.

SOT101 is an interleukin (IL)-15 superagonist that had demonstrated preclinical efficacy in various tumor models. Specifically, the agent prolonged survival and improved tumor regression in in vivo models. The agent also demonstrated a favorable toxicity profile preclinically.